Literature DB >> 11990717

The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats.

M Schneider1, M Koch.   

Abstract

Cannabinoids can disrupt short-term memory in humans and animals and induce learning deficits and other cognitive impairments. In the present study we examined the role of a full cannabinoid agonist in short-term memory, sensorimotor gating, and the acquisition and expression of an operant learning paradigm in rats. We tested the effects of the synthetic cannabinoid WIN 55,212-2 (0.6 and 1.2 mg/kg) on short-term memory in social and object recognition tests, on prepulse inhibition (PPI) of startle, as well as on lever pressing for palatable food. Injections of 0.6 and 1.2 mg/kg WIN 55,212-2 impaired recognition memory and PPI in a dose-dependent manner, but had no effect on lever-pressing acquisition or expression, or on food preference. The PPI deficit was reversed by the administration of 0.1 mg/kg haloperidol. These data suggest that the synthetic cannabinoid WIN 55,212-2 does not lead to a general impairment of learning in an appetitive instrumental task, but significantly affects short-term memory and sensorimotor integration. The impairment in recognition and PPI might be due to deficits in attention-based short-term information processing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11990717     DOI: 10.1097/00008877-200202000-00003

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  39 in total

1.  Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor.

Authors:  Emilio Fernandez-Espejo; Beatriz Galan-Rodriguez
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

Review 2.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

3.  Alterations to pre-pulse inhibition (PPI) in chronic cannabis users are secondary to sustained attention deficits.

Authors:  Kirsty Elizabeth Scholes; Mathew Thomas Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  2009-10-09       Impact factor: 4.530

4.  Cannabinoid CB₂ receptor-mediated regulation of impulsive-like behaviour in DBA/2 mice.

Authors:  Francisco Navarrete; José M Pérez-Ortiz; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Corticosteroid dependent and independent effects of a cannabinoid agonist on core temperature, motor activity, and prepulse inhibition of the acoustic startle reflex in Wistar rats.

Authors:  Avdesh Avdesh; Vincent Cornelisse; Mathew Thomas Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  2011-09-27       Impact factor: 4.530

6.  Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.

Authors:  Isabella Canazza; Andrea Ossato; Claudio Trapella; Anna Fantinati; Maria Antonietta De Luca; Giulia Margiani; Fabrizio Vincenzi; Claudia Rimondo; Fabiana Di Rosa; Adolfo Gregori; Katia Varani; Pier Andrea Borea; Giovanni Serpelloni; Matteo Marti
Journal:  Psychopharmacology (Berl)       Date:  2016-08-15       Impact factor: 4.530

7.  Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.

Authors:  Adriana M Marques; Michele V Macena; Aline R Cardoso; Camila S O Hammes; Fernanda M L Pinheiro; Newton G Castro; Gilda A Neves
Journal:  Psychopharmacology (Berl)       Date:  2020-02-24       Impact factor: 4.530

8.  The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats.

Authors:  Marco Bortolato; Gian Nicola Aru; Roberto Frau; Marco Orrù; Grant Christopher Luckey; Gianluca Boi; Gian Luigi Gessa
Journal:  Psychopharmacology (Berl)       Date:  2004-07-28       Impact factor: 4.530

Review 9.  Role of cannabis and endocannabinoids in the genesis of schizophrenia.

Authors:  Emilio Fernandez-Espejo; Maria-Paz Viveros; Luis Núñez; Bart A Ellenbroek; Fernando Rodriguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  2009-07-24       Impact factor: 4.530

10.  Chronic Delta9-tetrahydrocannabinol during adolescence increases sensitivity to subsequent cannabinoid effects in delayed nonmatch-to-position in rats.

Authors:  Jenny L Wiley; James J Burston
Journal:  Pharmacol Biochem Behav       Date:  2009-11-24       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.